Lynparza On Track For Broad Frontline Use In Prostate Cancer

Leading PARP Inhibitor’s Uses Keep Expanding

 
• By Andrew McConaghie

AstraZeneca and Merck & Co’s latest results put them far ahead of competitors in prostate cancer in reaching patient regardless of their mutational status.

AstraZeneca
Lynparza is one of a handful of targeted cancer therapies currently leading AstraZeneca's growth. • Source: Shutterstock: Elzbieta Krzysztof

More from Business

More from Scrip